Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
Authors
Keywords
Type 2 diabetes, HbA1c, Glucagon-like peptide-1 receptor agonists, Exenatide, Liraglutide, Lixisenatide, Albiglutide, Dulaglutide, Semaglutide, Cardiovascular risk factors, Cardiovascular outcomes
Journal
Current Diabetes Reports
Volume 18, Issue 10, Pages -
Publisher
Springer Nature America, Inc
Online
2018-08-31
DOI
10.1007/s11892-018-1043-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials
- (2018) Xiaoming Jia et al. CARDIOVASCULAR DRUGS AND THERAPY
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
- (2018) M Angelyn Bethel et al. Lancet Diabetes & Endocrinology
- A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data
- (2017) Evgenia Gourgari et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
- (2017) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- 9. Cardiovascular Disease and Risk Management
- (2016) DIABETES CARE
- 4. Lifestyle Management
- (2016) DIABETES CARE
- Carotid Intima-Media Thickness for Atherosclerosis
- (2016) Tomohisa Nezu et al. Journal of Atherosclerosis and Thrombosis
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus
- (2016) Jean-Luc Faillie et al. JAMA Internal Medicine
- Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
- (2015) Wei Ren Chen et al. AMERICAN HEART JOURNAL
- Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
- (2015) Sten Madsbad DIABETES OBESITY & METABOLISM
- Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention
- (2015) Tsuyoshi Nozue et al. HEART AND VESSELS
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study
- (2014) Manfredi Rizzo et al. Cardiovascular Diabetology
- Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers
- (2014) Eren Gurkan et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: A prospective study
- (2014) Gonzalo Díaz-Soto et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials
- (2014) Vivian A. Fonseca et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- (2014) Kathleen M Dungan et al. LANCET
- Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
- (2014) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- Cardioprotective Effects of Exenatide in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
- (2013) Jong Shin Woo et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
- (2013) J. Rosenstock et al. DIABETES CARE
- Is Glucose Control Important for Prevention of Cardiovascular Disease in Diabetes?
- (2013) E. Mannucci et al. DIABETES CARE
- Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials
- (2013) B. Wang et al. DIABETES OBESITY & METABOLISM
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of Ischemia
- (2012) Jacob Lønborg et al. Circulation-Cardiovascular Interventions
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus
- (2012) Linong Ji et al. Journal of Diabetes Investigation
- EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)
- (2011) William B. White et al. AMERICAN HEART JOURNAL
- The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus
- (2011) Marshall Elam et al. Clinical Lipidology
- Therapy in the Early Stage: Incretins
- (2011) S. Cernea et al. DIABETES CARE
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
- (2011) Jacob Lønborg et al. EUROPEAN HEART JOURNAL
- Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease
- (2011) Philip A Read et al. HEART
- DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
- (2011) Thomas Blevins et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection
- (2011) Amanda N. Long et al. Journal of Clinical Hypertension
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of flow-mediated dilation in humans: a methodological and physiological guideline
- (2010) Dick H. J. Thijssen et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition
- (2010) M. C. Bunck et al. DIABETES CARE
- Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents
- (2010) J. B. Buse et al. DIABETES CARE
- DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
- (2010) J. B. Buse et al. DIABETES CARE
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10)
- (2008) Robert Wilcox et al. AMERICAN HEART JOURNAL
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
- (2008) Kiwon Ban et al. CIRCULATION
- Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes
- (2008) J.-P. Courrèges et al. DIABETIC MEDICINE
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now